Knowledge Library

Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines

Delivery carriers are a critical component in the development of mRNA vaccines. Here, we describe the synthesis of a cationic polymer as a carrier for mRNA cancer vaccine delivery. In vivo results show that this polymer-based mRNA vaccine significantly delays tumor growth after vaccination of mice. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743697/  

Resource Type: Latest Science Publication
Resource Topic: Oncology Tumor Models

VIEW

KRAS-related Genetically Engineered Cell Lines and In Vivo Models

KRAS mutant proteins that drive cancer development are highly similar in sequence and structure. Direct inhibitors are most likely to bind to the catalytic domain of KRAS. However, recent studies have found that KRAS mutants can also be targeted by heterogeneous sites, to develop covalent inhibitors of KRAS mutants. The discovery of inhibitors that selectively …Read More >

Resource Type: Latest Science Presentation
Resource Topic: Biochemical Assays Biophysical Assays Cell-based Assays Cells and Protein Science Hit Finding Hit-to-Lead Lead Optimization Oncology Small Molecules Tumor Models

VIEW

CDK4/6 Inhibitor Resistant Breast Cancer Models

Leverage our extensive panel of CDK4/6 inhibitor resistant breast cancer models, including:  In vitro induced Palbociclib resistant MCF-7 cell line In vivo induced Palbociclib resistant MCF-7 model In vivo induced Abemaciclib resistant MCF-7 model In vivo induced Ribociclib resistant MCF-7 model

Resource Type: Latest Science Presentation
Resource Topic: Cell-based Assays Oncology Target-Specific Assays Tumor Models

VIEW

OncoWuXi Newsletter December 2022

Resource Type: Latest Science Newsletter
Resource Topic: Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Candidate Selection Cell-based Assays CRISPR/Cas9 DRUG DISCOVERY AND INNOVATION Hit Finding Hit-to-Lead Immunology Lead Optimization Oncology Phenotypic Assays Rare Diseases Target Identification and Validation Tumor Models

VIEW

How Does It Work? | Antibody Drug Conjugates

In this week’s installment of our “How Does It Work?” video series, we explore Antibody Drug Conjugates. Monoclonal antibodies are highly versatile molecules that we can modify to generate new and improved cancer therapies. Here we have a type of modified antibody, known as an antibody drug conjugate, or ADC. The ADC contains two antigen …Read More >

Resource Type: Video
Resource Topic: Antibody Drug Conjugate Biochemical Assays Cell-based Assays Oncology Target Identification and Validation Target-Specific Assays Tumor Models

VIEW

OncoWuXi Newsletter: June 2022

WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform

Resource Type: Newsletter
Resource Topic: Antibodies Cell-based Assays Hit-to-Lead in vivo Pharmacology Lead Optimization Oncology Target-Specific Assays Tumor Models

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platform. Integrated Chemistry and Biology Research Platform | From Discovery to Candidate Selection and Beyond

Resource Type: Brochure
Resource Topic: Antibodies Antibody Drug Conjugate Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Biophysical Assays Candidate Selection CAR-T Cell Cardiovascular & Metabolic Diseases Cell Therapies Cell-based Assays Cells and Protein Science Central Nervous System & Pain Chemical Biology and Proteomics CRISPR/Cas9 Dermatology Discovery Chemistry DNA-Encoded Library (DEL) DRUG DISCOVERY AND INNOVATION Fragment-Based Drug Discovery Gene Manipulation Gene Therapies High-throughput screening (HTS) Hit Finding Hit-to-Lead Immunology in silico services in vitro biology in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Liver Diseases Mass Spectrometry-based Assays Metabolic Diseases NASH Oligonucleotides Oncology Oncolytic Viruses Ophthalmology Phenotypic Assays Quantum Mechanics Rare Diseases Respiratory Diseases Safety and Early Toxicity Screening Libraries Screening Services Small Molecules Structural Biology Target Identification and Validation Target-Specific Assays Targeted Protein Degradation TECHNOLOGY PLATFORMS THERAPEUTIC AREAS THERAPEUTIC MODALITIES Tumor Models

VIEW

Brain metastasis mouse models for the evaluation of multikinase inhibitors on ROS1-fusion-positive lung cancer

Lung cancer is the leading cause of cancer-related death worldwide.  Nearly 80% of lung cancers are non-small cell lung cancer (NSCLC) and 60% of them are diagnosed at the metastatic stage. Brain metastases affect more than 20% of NSCLC patients with poor prognosis and disabling symptoms. However, few therapies have been approved for the treatment …Read More >

Resource Type: Poster
Resource Topic: in vivo Pharmacology Lead Optimization Oncology Small Molecules Tumor Models

VIEW

Intra-carotid artery brain metastasis models for the evaluation of lung and breast cancer drugs

Non-CNS metastatic brain cancer is approximately 10 times more common than CNS cancer. Lung cancer and breast cancer account for most brain metastasis. KRAS-mutant NSCLC composes a third lung adenocarcinoma, among which 17% to 55% will develop brain metastases. Likewise, more than a third HER2-positive breast cancer will develop brain metastasis. Among existing animal models, …Read More >

Resource Type: Poster
Resource Topic: in vivo Pharmacology Oncology Tumor Models

VIEW


Resource Topics